Neuren Pharmaceuticals' (ASX:NEU) Jon Pilcher speaks to Proactive's Andrew Scott following the news they've received approval for the final stage of its NNZ-2591 clinical trial. The Phase 1 trial in Australia is evaluating the safety, tolerability and pharmacokinetics of the drug in healthy adult volunteers before advancing to Phase 2 trials in patients next year.
viewNeuren Pharmaceuticals Ltd
Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial
Quick facts: Neuren Pharmaceuticals Ltd
Price: 1.25 AUD
ASX:NEU
Market: ASX
Market Cap: $147.01 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Neuren Pharmaceuticals Ltd named herein, including the promotion by the Company of Neuren Pharmaceuticals Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Tech
K2fly's financial outlook remains strong leading into H2 FY21 off the back...
6 days, 1 hour ago
Mining
Castillo Copper acts on strong Big One results and buoyant copper markets...
4 days, 7 hours ago
Tech
Archer Materials makes progress with patent applications for 12CQ quantum...
6 days, 5 hours ago
